Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	9	JUL 27	CA/CAplus enhanced with new citing references
NEWS	10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	11	JUL 21	USGENE adds bibliographic and sequence information
NEWS	12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS	13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS	14	AUG 08	Improve STN by completing a survey and be entered to win a gift card
NEWS	15	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* http://www.zoomerang.com/Survey/?p=WEB229H4S8Q5UL                    *
*                                                                      *
************************************************************************

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:04:10 ON 14 AUG 2009

=> File Medline EMBASE Biosis Caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'MEDLINE' ENTERED AT 16:04:19 ON 14 AUG 2009

FILE 'EMBASE' ENTERED AT 16:04:19 ON 14 AUG 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:04:19 ON 14 AUG 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 16:04:19 ON 14 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> S (Rab11A) (8A) (HIV-1)
L1            2 (RAB11A) (8A) (HIV-1)

=> S (Rab11A) (P) (HIV-1)
L2            8 (RAB11A) (P) (HIV-1)

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l2
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L2
L3             3 DUPLICATE REMOVE L2 (5 DUPLICATES REMOVED)

=> d l3 1-3 bib ab

L3   ANSWER 1 OF 3     MEDLINE on STN                    DUPLICATE 1
AN   2008337671     MEDLINE
DN   PubMed ID: 18406652
TI   Statin-induced inhibition of HIV-1 release from latently infected U1 cells
     reveals a critical role for protein prenylation in HIV-1 replication.
AU   Amet Tohti; Nonaka Mizuho; Dewan Md Zahidunnabi; Saitoh Yasunori; Qi
     Xiaohua; Ichinose Shizuko; Yamamoto Naoki; Yamaoka Shoji
CS   Department of Molecular Virology, Graduate School of Medicine, Tokyo
     Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510,
     Japan.
SO   Microbes and infection / Institut Pasteur, (2008 Apr) Vol. 10, No. 5, pp.
     471-80.  Electronic Publication: 2008-01-20.
     Journal code: 100883508. ISSN: 1286-4579.
CY   France
DT   Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA   English
FS   Priority Journals
EM   200807
```

ED Entered STN: 28 May 2008
Last Updated on STN: 16 Jul 2008
Entered Medline: 15 Jul 2008

AB Latent infection of human immunodeficiency virus type 1 (HIV-1) represents a major hurdle in the treatment of acquired immunodeficiency syndrome (AIDS) patients. Statins were recently reported to suppress acute HIV-1 infection and reduce infectious virion production, but the precise mechanism of inhibition has remained elusive. Here we demonstrate that lypophilic statins suppress HIV-1 virion release from tumor necrosis factor alpha-stimulated latently infected U1 cells through inhibition of protein geranylgeranylation, but not by cholesterol depletion. Indeed, this suppression was reversed by the addition of geranylgeranylpyrophosphate, and a geranylgeranyltransferase-1 inhibitor reduced HIV-1 production. Notably, silencing of the endogenous Rab11a GTPase expression in U1 cells by RNA interference destabilized Gag and reduced virion production both in vitro and in NOD/SCID/gammac null mice. Our findings thus suggest that small GTPase proteins play an important role in HIV-1 replication, and therefore could be attractive molecular targets for anti-HIV-1 therapy.

L3 ANSWER 2 OF 3 MEDLINE on STN DUPLICATE 2
AN 2006111648 MEDLINE
DN PubMed ID: 16497224
TI The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release.
AU Varthakavi Vasundhara; Smith Rita M; Martin Kenneth L; Derdowski Aaron; Lapierre Lynne A; Goldenring James R; Spearman Paul
CS Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232-2581, USA.
NC DK38063 (United States NIDDK NIH HHS)
DK48370 (United States NIDDK NIH HHS)
P30 AI1054999 (United States NIAID NIH HHS)
R01 AI058828 (United States NIAID NIH HHS)
SO Traffic (Copenhagen, Denmark), (2006 Mar) Vol. 7, No. 3, pp. 298-307.
Journal code: 100939340. ISSN: 1398-9219.
CY Denmark
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
LA English
FS Priority Journals
EM 200605
ED Entered STN: 28 Feb 2006
Last Updated on STN: 25 May 2006
Entered Medline: 24 May 2006

AB The HIV-1 accessory gene product Vpu is required for efficient viral particle release from infected human cells. The mechanism by which Vpu enhances particle assembly or release is not yet defined. Here, we identify an intracellular site that is critical for Vpu-mediated enhancement of particle release. Vpu was found to co-localize with markers for the pericentriolar recycling endosome. Expression of dominant negative mutants of Rab11a and myosin Vb that disrupt protein sorting through the recycling endosome abrogated the ability of Vpu to augment particle release. Remarkably, the effects of blocking recycling endosome function on HIV particle release were demonstrable only in human cell lines known to be responsive to Vpu, while no effect on particle release was seen in African green monkey cells. Inhibition of recycling endosome function in human cells also blocked the ability of HIV-2 envelope to enhance particle release. These studies indicate that Vpu and HIV-2 envelope glycoprotein enhance particle release via a common

mechanism that requires the activity of the pericentriolar recycling endosome.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1075825 CAPLUS
DN 143:360061
TI G proteins RAB9A and RAB11A playing a role in viral infection processes as targets for prevention of infectious disease
IN Hodge, Thomas W.; McDonald, Natalie J.; Rubin, Donald; Shaw, Michael W.; Sanchez, Anthony; Murray, James L.
PA The Government of the United States of America as Represented by the Secretary, Department of Health and Human Services Centers for Disease Control and Prevention, USA; Vanderbilt University
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092924	A2	20051006	WO 2005-US6396	20050224
	WO 2005092924	A3	20060511		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005226779	A1	20051006	AU 2005-226779	20050224
	CA 2557426	A1	20051006	CA 2005-2557426	20050224
	EP 1723177	A2	20061122	EP 2005-758743	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	JP 2008506356	T	20080306	JP 2007-500800	20050224
	EP 1958964	A2	20080820	EP 2008-5922	20050224
	EP 1958964	A3	20090107		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 20070087008	A1	20070419	US 2006-590844	20060824
	IN 2006KN02795	A	20070601	IN 2006-KN2795	20060925
PRAI	US 2004-547328P	P	20040224		
	EP 2005-758743	A3	20050224		
	WO 2005-US6396	W	20050224		

AB The G proteins RAB9A and RAB11A that play important roles in the regulation of cellular processes are found to play a role in processes used by pathogens in the infection of host cells and therefore may be targets for the prevention and treatment of infection. Exemplary pathogens include those that use a lipid raft. SiRNAs against a series of genes were tested for the effects on the infection of HIV-1 in JC53-BL cells. Lowered efficiency of infection were associated with lowered levels of mRNA for RAB9A and RAB11A. SiRNAs against proteins modulating RAB9A activity also limited the ability of HIV-1 to infect cells.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT